U.S. President Donald Trump has pledged to slash the cost of prescription medications in the United States by as much as 500% to 1500%, a target that would theoretically mean drug manufacturers paying patients to take their products. While the claim has sparked skepticism, the promise comes amid mounting pressure over the nation’s soaring pharmaceutical costs.
Trump’s comments, made during a July reception with members of Congress, were followed by letters sent to the heads of 17 major pharmaceutical companies urging them to align U.S. prices with those in other developed nations.
Trump’s Pledge and the Administration’s Strategy
In his remarks, Trump insisted, “This is something that nobody else can do. We’re gonna get the drug prices down. Not 30 or 40% which would be great, not 50 or 60, no. We’re gonna get ‘em down 1,000%, 600%, 500%, 1,500%.” according to a video posted on X. While the numbers are mathematically impossible beyond 100%, they reflect his intention to apply maximum pressure on pharmaceutical manufacturers.
According to the White House, letters to companies including Pfizer, Merck, AstraZeneca, and Johnson & Johnson outlined steps to lower costs. These include providing “most-favored-nation” pricing for Medicaid patients, ensuring U.S. prices are not higher than in other developed countries, and cutting out middlemen to allow direct sales to patients.
The administration also indicated it may use trade measures to push for higher international drug prices, allowing firms to reinvest any additional revenue into U.S. price reductions. The White House warned that, should the industry fail to comply, it would “deploy every tool in our arsenal” to combat what it described as “abusive drug pricing practices.”
Why Americans Pay More for Medication
According to a RAND Health Quarterly report published in June 2024, drug prices in the U.S. are almost three times higher than in 33 other high-income countries. This disparity stems from limited competition among pharmaceutical giants, the influence of pharmacy benefit managers, and high marketing costs, all of which add layers to the final price paid by consumers.
An executive order signed by Trump in May, citing that the U.S. represents “less than five percent of the world’s population and yet funds around three quarters of global pharmaceutical profits.” tasked Health Secretary Robert F. Kennedy, Jr. with facilitating direct-to-consumer purchasing programs at the most-favored-nation price.
According to the KFF, most Americans remain deeply concerned about prescription costs, which often outpace inflation. Despite past state-level initiatives, such as California’s Proposition 61, comprehensive federal solutions remain elusive, leaving drug affordability a persistent issue at the heart of the U.S. healthcare debate.
